LINK Medical and Ectin Research AB have signed an agreement appointing LINK Medical Research AB to run the Phase I/II clinical study of the treatment of metastatic bladder cancer patients with the drug candidate MFA-370. Ectin Research aims to submit its clinical trial application (CTA) to the Swedish Medical Products Agency, in collaboration with LINK Medical, followed by additional regulatory applications in two other countries.
Bladder cancer is one of the most aggressive cancers; 50-70% of tumours recur and 10-20% become metastatic. Current treatments of metastatic bladder cancer…
Biocair recently opened a new office in Chicago, bringing the total number of US offices to nine. This addition to Biocair’s global network is just one of several investments made in the last year, all part of the company’s efforts to further expand its industry-leading supply chain solutions for life sciences.
The new facility will accommodate certified packaging and conditioning areas for a wide range of temperatures, including an advanced liquid nitrogen service station, as well as office space for Operations staff.
June Rivera, Operations Development Director at Biocair, said:
“…
OXFORD, UK June 24th, 2021 – PrecisionLife Limited, a global healthcare combinatorial analytics company, announces that it has appointed Ray Pawlicki as Executive Chair to the Board of Directors.
Widely recognized as a leader in informatics across pharma and biotech, he will work closely with the PrecisionLife Board and CEO Steve Gardner to help steer the strategic growth of the company.
Mr. Pawlicki’s appointment underlines PrecisionLife’s ambition to be a major player driving the next wave of precision medicine. Its unique combinatorial analytics platform generates more insights into the…
SOMERSET, N.J. – June 24, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it has reached an agreement to acquire RheinCell Therapeutics GmbH, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs). Upon completion, the acquisition will build upon Catalent’s existing custom cell therapy process development and manufacturing capabilities with proprietary GMP cell lines for iPSC-based therapies.…
Leiden, The Netherlands, 23 June 2021: CellPoint, a cell therapy company developing CAR-T therapeutics for use at the point-of-care, announces an agreement with Lonza’s Personalized Medicine Business Unit to employ Lonza’s Cocoon® Platform for clinical manufacturing of CellPoint’s CAR-T cell therapies at the point-of-care, more rapidly and at lower cost.
CellPoint is developing various CAR-T immunotherapies to treat multiple cancers. One of the key hurdles in making these therapies more accessible to larger patient populations is the difficulty in manufacturing at-scale, robustly, and close…
It has been more than two years that Data Protection Authorities of EU Member States (‘DPAs’) started to perform data protection audits. As part of their general task of monitoring compliance with the principles laid down by the General Data Protection Regulation (“GDPR”), each competent DPA may carry out inspections and impose sanctions. Whether you are data controller or processor, you may therefore be subject to an audit at any time. That is why all organizations need to be ready now.
A DPA audit may occur generally as a result of a complaint or request from a data subject, following a…
• The partnership will support the progression of PY314, the first of Pionyr’s Myeloid TuningTM antibodies to enter the clinic
• Pionyr will use Abcam’s EPR20243 clone to evaluate TREM2 levels in tissue samples for potential future development as a CDx
• Abcam is Pionyr’s preferred partner for the long-term provision of anti-TREM2 antibody, suitable for use throughout the diagnostics development process
South San Francisco, US and Cambridge, UK – 22 June 2021 – Today Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body’s anti-tumor…
Tokyo, Japan and Cambridge, UK, 23 June 2021 – Sosei Group Corporation (“the Company”; TSE: 4565) today announces that the first healthy subject has been dosed with HTL0022562 in a Phase 1 clinical study. HTL0022562 (also known as BHV3100) is a novel, small molecule CGRP* receptor antagonist discovered by Sosei Heptares and the lead compound in a portfolio of CGRP antagonists licensed to Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN) in December 2020 for development as new therapies for CGRP-mediated disorders.
The trial is a Phase 1, randomized, double-blind, placebo-…
AMSBIO invite the global research community to the 2021 annual meeting of the ISSCR, the leading professional organization of stem cell scientists, to discover how iPSCs and organoids can be used in COVID-19 drug discovery research.At this virtual meeting - Dr. Kazuo Takayama from the renowned Center for iPS Cell Research and application (CiRA) at Kyoto University will be giving a unique insight into his recent pioneering research that has successfully modelled the SARS-CoV-2 life cycle in undifferentiated iPSCs, which were previously uninfectable. This innovation showcase…
CAMBRIDGE, England--(BUSINESS WIRE)--Apollo Therapeutics, a portfolio-based biopharmaceutical company rapidly advancing potentially transformative treatments based on breakthrough discoveries, has completed a $145 million (over £100 million) financing. The financing was led by Patient Square Capital, which will take a controlling position in the business, with participation from additional investors including Rock Springs Capital, Reimagined Ventures and UCL Technology Fund. Proceeds from the investment will support advancement of Apollo’s robust pipeline into development, expansion of the…